Comparison of Effect of Leukotriene Biosynthesis Blockers and Inhibitors of Phosphodiesterase Enzyme in Patients with Bronchial Hyperreactivity

Naim Morina; Arsim Haliti; Ali Iljazi; Drita Islami; Sadi Bexheti; Adnan Bozalija; Hilmi Islami

doi:10.3889/oamjms.2018.187

Authors

Naim Morina Department of Pharmacy, Faculty of Medicine, University of Prishtina, Prishtina, Kosovo
Arsim Haliti Department of Pharmacy, Faculty of Medicine, University of Prishtina, Prishtina, Kosovo
Ali Iljazi Kosovo Occupational Health Institute, Gjakovo, Kosovo
Drita Islami Department of Pharmacology, Faculty of Medicine, University of Prishtina, Kosovo
Sadi Bexheti Department of Anatomy, Faculty of Medicine, University of Prishtina, Kosovo
Adnan Bozalija Department of Pharmacy, Faculty of Medicine, University of Prishtina, Prishtina, Kosovo
Hilmi Islami Department of Pharmacology, Faculty of Medicine, University of Prishtina, Kosovo

DOI:

https://doi.org/10.3889/oamjms.2018.187

Keywords:

Bronchial asthma, Zileuton, Diprophylline and tiotropium bromide

Abstract

AIM: Blocking effect of leukotriene biosynthesisâ€“zileuton and blocking the effect of phosphodiesterase enzymeâ€“diprophylline in the treatment of patients with bronchial asthma and bronchial increased reactivity, and tiotropium bromide as an antagonist of the muscarinic receptor studied in this work.

METHODS: Parameters of the lung function are determined with Body plethysmography. The resistance of the airways (Raw) was registered and measured was intrathoracic gas volume (ITGV), and specific resistance (SRaw) was also calculated. For the research, administered was zileuton (tabl. 600 mg) and diprophylline (tabl. 150 mg).

RESULTS: Two days after in-house administration of leukotriene biosynthesis blockerâ€“zileuton (4 x 600 mg orally), on the day 3 initial values of patients measured and afterwards administered 1 tablet of zileuton, and again measured was Raw and ITGV, after 60, 90 and 120 min. and calculated was SRaw; (p < 0.01). Diprophylline administered 7 days at home in a dose of (2 x 150 mg orally), on the day 8 to same patients administered 1 tablet of diprophylline, and performed measurements of Raw, ITGV, after 60, 90 and 120 min, and calculated the SRaw (p < 0.05). Treatment of the control group with tiotropium bromide - antagonist of the muscarinic receptor (2 inh. x 0.18 mcg), is effective in removal of the increased bronchomotor tonus, by also causing the significant decrease of the resistance (Raw), respectively of the specific resistance (SRaw), (p < 0.05).

CONCLUSION: Effect of zileuton in blocking of leukotriene biosynthesis is not immediate after oral administration, but the effect seen on the third day of cys-LTsâ€™ inhibition, and leukotriene B4 (LTB4) and A4 (LTA4) in patients with bronchial reactivity and bronchial asthma, which is expressed with a high significance, (p < 0.01). Blockage of phosphodiesterase enzymeâ€“diprophylline decreases the bronchial reactivity, which is expressed with a moderate significance, (p < 0.05).

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Backman, John D Blakey DJ, Woolnough K, Fellows K, Walker S, Thomas M, et al. Assessing the risk of attack in the management of asthma: a review and proposal for revision of the current control-centred paradigm. World Allergy Organization Journal. 2014; 7:1. https://doi.org/10.1186/1939-4551-7-1 PMid:24383710 PMCid:PMC3929247

Peters-Golden M, Henderson WR Jr. Mechanisms of disease: leukotrienes. NEJM. 2007; 18:1798â€“854.

Okunishi K, Peters-Golden M. Leukotrienes and airway inflammation. Biochemica et Biophysica Acta. 2011; 11:1096â€“102. https://doi.org/10.1016/j.bbagen.2011.02.005 PMid:21352897 PMCid:PMC3136588

Schmidt J, Bell F, Akam E, et al. Biochemical and pharmacological characterization of AZD1981, an orally available selective DP2 antagonist in clinical development for asthma. Br J Pharmacol. 2013; 168:1626-38. https://doi.org/10.1111/bph.12053 PMid:23146091 PMCid:PMC3605871

Chowdhury BA, Seymour SM, Levenson MS. Assessing the Safety of AddingLABAs to Inhaled Corticosteroids for Treating Asthma. N Engl J Med. 2011; 364:2473âˆ’5. https://doi.org/10.1056/NEJMp1104375 PMid:21714647

Fredholm BB, and Persson CG. Xanthine derivaties as adenosine receptor antagonists. Eur J Pharmacol. 1982; 87:673-676. https://doi.org/10.1016/0014-2999(82)90359-4

Torphy TJ, Undem BJ, Cieslinski LB, et al. Identification, characterization, and functional role of phosphodiesterase isozymes in human airway smooth muscle. J Pharmacol Exp Ther. 1993; 265:1213-1223. PMid:8389856

Johnson M. Molecular mechanisms of Î²2-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol. 2006; 117:18âˆ’24. https://doi.org/10.1016/j.jaci.2005.11.012 PMid:16387578

Bousquet J, Aubier M, Sastre J, et al. Comparison of rofl umilast, an oral anti- inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy. 2006; 61:72-8. https://doi.org/10.1111/j.1398-9995.2005.00931.x PMid:16364159

Singh D, Petavy F, MacDonald A, et al. The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Resp Res. 2010; 11:26. https://doi.org/10.1186/1465-9921-11-26 PMid:20193079 PMCid:PMC2841147

Peters-Golden M, Henderson WR. Jr. Leukotrienes. N Engl J Med. 2007; (357):1841â€“ 54.

Bateman ED, Izquierdo JL, Harnest U,et al. Efficacy and safety of rofl umilast in the treatment of asthma. Ann Allergy. Asthma Immunol. 2006; 96:679-86. https://doi.org/10.1016/S1081-1206(10)61065-4

Scott JP, Peters-Golden M. Antileukotriene Agents for the Treatment of Lung Disease. AJRCCM. 2013;5:538âˆ’44. https://doi.org/10.1164/rccm.201301-0023PP

Barnes NCand Miller CJ. Effect of leukotrine receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: An intergrated analysis of zafirlukast trials. Thorax. 2000; 55:478-483. https://doi.org/10.1136/thorax.55.6.478 PMid:10817796 PMCid:PMC1745774

Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast,inhaledbeslomethasone, and placebo for chronic asthma: A randomized, controlled trial. Montelukast. Beclomethasone Study Group. Am Intern Med. 1999; 730:487-495. https://doi.org/10.7326/0003-4819-130-6-199903160-00005

Lofdahl CG, Reiss TF, Leff JA, et al. Randomized, placebo-controlldtrial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. MBJ. 1999; 379:87-90. https://doi.org/10.1136/bmj.319.7202.87

Morina N, Iljazi A, Iljazi F, Hyseini K, Bozalia A,Islami H. Effect of antileukotriene (zileuton) in patients with bronchial asthma (emphasized reactors, moderate reactors, and non-reactors). RJPBCS. 2017; 8 (5): 334-342.

Fredholm BB and Persson CG. Xanthine derivaties as adenosine receptor antagonists. Eur J Pharmacol. 1982; 87:673-676. https://doi.org/10.1016/0014-2999(82)90359-4

Feoktistov I, Polosa R, Holgate ST andBiaggioni I. Adenosine A2B receptors: A novel therapeutic target in asthma? Trends Pharmacol. ScL. 1998; 79:148-153.

Ito K, Lim S, Caramori G, et al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to devrease inflammatory gene expression. Proc Natl Acad Sci. USA. 2002; 99:8921-8926. https://doi.org/10.1073/pnas.132556899 PMid:12070353 PMCid:PMC124399

Paulwels R, Van Renterghem D, Van Streaten M, et al. The effect of theophylline and enprofylline on allergen â€“ induced bronchoconstriction. J Allergy Clin Immunol, 1985; 76:583-590. https://doi.org/10.1016/0091-6749(85)90779-1

Okunishi K, Peters-Golden M. Leukotrienes and airway inflammation. Biochemica et Biophysica Acta. 2011; 11:1096â€“102. https://doi.org/10.1016/j.bbagen.2011.02.005 PMid:21352897 PMCid:PMC3136588